We Think Shareholders May Want To Consider A Review Of Medicskin Holdings Limited's (HKG:8307) CEO Compensation Package
We Think Shareholders May Want To Consider A Review Of Medicskin Holdings Limited's (HKG:8307) CEO Compensation Package
Key Insights
主要见解
- Medicskin Holdings to hold its Annual General Meeting on 6th of September
- Salary of HK$4.22m is part of CEO Kwok Leung Kong's total remuneration
- Total compensation is 340% above industry average
- Medicskin Holdings' EPS declined by 91% over the past three years while total shareholder loss over the past three years was 52%
- 密迪斯肌控股将于九月六日举行年度股东大会
- CEO郭良刚的总薪酬中包括4,220,000港元的工资
- 总补偿超过行业平均水平的340%
- 在过去三年中,密迪斯肌控股的每股收益下降了91%,股东总损失在过去三年中为52%
Shareholders will probably not be too impressed with the underwhelming results at Medicskin Holdings Limited (HKG:8307) recently. At the upcoming AGM on 6th of September, shareholders can hear from the board including their plans for turning around performance. They will also get a chance to influence managerial decision-making through voting on resolutions such as executive remuneration, which may impact firm value in the future. We present the case why we think CEO compensation is out of sync with company performance.
股东们可能对密迪斯肌控股有限公司(HKG:8307)最近表现不佳的结果并不满意。在即将到来的9月6日的股东大会上,股东们可以听取董事会的发言,包括他们的扭转业绩的计划。他们还将有机会通过对诸如执行薪酬等决议进行投票来影响管理决策,这可能会在未来影响公司价值。我们提出了我们认为首席执行官薪酬与公司绩效脱节的理由。
How Does Total Compensation For Kwok Leung Kong Compare With Other Companies In The Industry?
Kwok Leung Kong的总补偿如何与该行业的其他公司比较?
According to our data, Medicskin Holdings Limited has a market capitalization of HK$52m, and paid its CEO total annual compensation worth HK$7.1m over the year to March 2024. We note that's an increase of 15% above last year. We note that the salary of HK$4.22m makes up a sizeable portion of the total compensation received by the CEO.
根据我们的数据,密迪斯肌控股有限公司的市值为5200万港元,并且其首席执行官在截至2024年3月的一年中总薪酬为710万港元。我们注意到这比去年增加了15%。我们注意到42.2万港元的工资占首席执行官总薪酬的相当大比例。
On comparing similar-sized companies in the Hong Kong Healthcare industry with market capitalizations below HK$1.6b, we found that the median total CEO compensation was HK$1.6m. This suggests that Kwok Leung Kong is paid more than the median for the industry. Furthermore, Kwok Leung Kong directly owns HK$36m worth of shares in the company, implying that they are deeply invested in the company's success.
在将香港卫生保健行业中市值低于16亿港元的规模相似公司进行比较时,我们发现中位数总首席执行官薪酬为160万港元。这表明郭亮刚的薪酬高于该行业的中位数。此外,郭亮刚直接持有公司价值3600万港元的股份,暗示他们对公司的成功有着深入的投资。
Component | 2024 | 2023 | Proportion (2024) |
Salary | HK$4.2m | HK$4.6m | 59% |
Other | HK$2.9m | HK$1.6m | 41% |
Total Compensation | HK$7.1m | HK$6.2m | 100% |
组成部分 | 2024 | 2023 | 比例(2024年) |
薪资 | 420万元港元 | 460万元港元 | 59% |
其他 | 290万元港币 | 160万港元 | 41% |
总补偿 | 重要提示:虽然密迪斯肌控股是一只令人兴奋的股票,但我们理解投资者可能正在寻找没有负债和巨额回报的公司。您可能会在这份有高roe和低负债的有趣公司名单中找到更好的选择。 | HK$6.2m | 100% |
On an industry level, around 72% of total compensation represents salary and 28% is other remuneration. In Medicskin Holdings' case, non-salary compensation represents a greater slice of total remuneration, in comparison to the broader industry. If salary dominates total compensation, it suggests that CEO compensation is leaning less towards the variable component, which is usually linked with performance.
![1725061542122](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240831/43145525-0-3d8ea948ed7873ca748929c96eebbc7d.webp/bigjpg)
A Look at Medicskin Holdings Limited's Growth Numbers
Over the last three years, Medicskin Holdings Limited has shrunk its earnings per share by 91% per year. Its revenue is up 8.4% over the last year.
The decline in EPS is a bit concerning. The modest increase in revenue in the last year isn't enough to make us overlook the disappointing change in EPS. These factors suggest that the business performance wouldn't really justify a high pay packet for the CEO. Although we don't have analyst forecasts, you might want to assess this data-rich visualization of earnings, revenue and cash flow.
Has Medicskin Holdings Limited Been A Good Investment?
With a total shareholder return of -52% over three years, Medicskin Holdings Limited shareholders would by and large be disappointed. So shareholders would probably want the company to be less generous with CEO compensation.
To Conclude...
总之...
Along with the business performing poorly, shareholders have suffered with poor share price returns on their investments, suggesting that there's little to no chance of them being in favor of a CEO pay raise. At the upcoming AGM, the board will get the chance to explain the steps it plans to take to improve business performance.
随着业务表现不佳,股东的投资回报率也随之下降,这表明他们很少有机会支持加薪。在即将举行的股东大会上,董事会将有机会解释其计划改善业务绩效。
CEO compensation can have a massive impact on performance, but it's just one element. That's why we did some digging and identified 1 warning sign for Medicskin Holdings that investors should think about before committing capital to this stock.
Important note: Medicskin Holdings is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。